Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.

@article{Nieken1995RecombinantHI,
  title={Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.},
  author={J. Nieken and Nanno H. Mulder and Jan Buter and Edo Vellenga and Pieter C. Limburg and D. Albertus Piers and E G E Liesbeth de Vries},
  journal={Blood},
  year={1995},
  volume={86 3},
  pages={900-5}
}
Initial studies have shown that recombinant human interleukin-6 (rhIL-6) induces anemia. Until now, the pathophysiologic mechanism of this induced anemia has been unknown. To unravel the underlying mechanism, we examined 15 cancer patients receiving rhIL-6 as an antitumor immunotherapy in a phase II study. rhIL-6 was administered subcutaneously at 150 micrograms once daily for 6 consecutive weeks. Various hematologic and biochemical parameters were measured weekly during rhIL-6 treatment and 4… CONTINUE READING